by Madaline Spencer | Jul 1, 2025
Saad Usmani, MD, Myeloma Specialist and Cellular Therapist at Memorial Sloan Kettering Cancer Center, discusses results from the CEPHEUS clinical trial in multiple myeloma (MM). MM is a bone marrow-based plasma cell neoplasm characterized by a serum...
by Madaline Spencer | Jun 30, 2025
Dirk Arnold, MD, PhD, Director of the Asklepios Tumorzentrum Hamburg, discusses the OrigAMI-2 clinical trial in left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC). Approximately 50% of patients diagnosed with colorectal cancer have...
by Madaline Spencer | Jun 27, 2025
Peter Voorhees, MD, Atrium Health and Levine Cancer Institute, Wake Forest University School of Medicine, discusses results from the CARTITUDE-1 study in patients with multiple myeloma (MM). MM is a bone marrow-based plasma cell neoplasm characterized by...
by Madaline Spencer | Jun 25, 2025
The U.S. Food and Drug Administration (FDA) has approved Harliku (nitisinone) for the treatment of adult patients with alkaptonuria. Alkaptonuria (AKU) is an ultra-rare inherited condition that causes urine to turn black when exposed to air as the result of...
by Madaline Spencer | Jun 25, 2025
Jonathan Strober, MD, Director of the Neuromuscular Clinic and Professor of Pediatrics and Neurology at the University of California at San Francisco, discusses the implications of nipocalimab’s approval to treat pediatric patients with myasthenia gravis (MG)....
